IL17A and systemic lupus erythematosus: Treatment of MRL/lpr lupus-prone mice with IL-2-recombinant adeno-associated virus led to amelioration of lupus-related skin, lung and renal pathological lesions, accompanied by a significant reduction of IL-17-producing DNTC and increase in Treg number [59].